Episodes (Page 3)
✨
Ralf Schmid discusses evolving use of large animal models in gene therapy.
✨
Opus Genetics advances gene therapies for inherited retinal diseases.
George Magrath
✨
Aegle Therapeutics pioneers extracellular vesicle therapies.
Gloria Matthews
✨
Halloran Consulting Group discusses CGT development and regulatory challenges.
Monika Swietlicka
✨
Generate:Biomedicines harnesses AI and synthetic biology for cell therapies.
Alex Snyder
✨
BioCardia's evolution into autologous and allogeneic cell therapy development.
✨
Cancer Research Institute discusses advancing cancer immunotherapy research.
✨
Exploring challenges and opportunities in CGT biotech growth and investment.
Audrey Greenberg
✨
Atsena Therapeutics develops treatments for inherited retinal diseases.
✨
Cellenkos pioneers cord blood-derived Treg cell therapies for autoimmune diseases.
✨
Deloitte Consulting discusses distributed manufacturing for CGT capacity.
Omkar Kawalekar
✨
Tenaya Therapeutics explores gene therapies for heart diseases.
✨
Precigen utilizes gorilla adenovirus vectors for large genetic payloads.
Helen Sabzevari
✨
Artiva Biotherapeutics discusses NK cell therapy for autoimmune disease.
Christopher Horan
✨
Roswell Park discusses automation in CGT manufacturing.
Christopher Choi
✨
AskBio discusses gene therapy challenges for congestive heart failure.
Lothar Roessig
✨
BlueRock Therapeutics explores dopamine-restoring cell therapy for Parkinson's.
Amit Rahkit
✨
Globalization's impact on patient access to cell and gene therapies discussed.
Rita Johnson-Greene
✨
Adaptimmune discusses TCR T-cell therapy and the TECELRA trial.
Dennis Williams
✨
Kiji Therapeutics discusses iPSC-MSC therapy for inflammatory diseases.
Miguel Forte